Full Text View
Tabular View
No Study Results Posted
Related Studies
QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
This study is currently recruiting participants.
Study NCT00568425   Information provided by Stanford University
First Received: December 4, 2007   Last Updated: November 19, 2008   History of Changes

December 4, 2007
November 19, 2008
September 2005
 
 
 
Complete list of historical versions of study NCT00568425 on ClinicalTrials.gov Archive Site
 
 
 
QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
Quality of Life and Functional Outcomes After Combined Modality Therapy for Anal Cancer: A Comparison of Conventional Versus Intensity-Modulated Radiation Therapy (ANAL0002)

The purpose of this study is show that intensity-modulated radiotherapy (IMRT), as compared with conventional radiotherapy, improves the precision of tumor targeting and reduces the acute and late effects of radiation toxicity when used to treat anal cancer. Results from this work will provide a basis for incorporating the use of IMRT to treat anal cancer in future treatment protocols.

The objectives of this study are three-fold. First, we would like to learn and compare the doses of radiation received by the tumor and the normal tissues in anal cancer patients treated with IMRT, and in those treated with conventional radiotherapy. Second, we wish to compare the acute effects of radiation treatment in both groups of patients. Our third objective is to evaluate the late effects of radiation treatment in both groups of patients. The first two objectives will be studied using a retrospective analysis of patients with anal cancer treated at Stanford University Medical Center. The third objective will require these patients to complete and return three quality of life questionnaires.

 
Observational
Other
Anal Cancer
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
30
 
 

Inclusion Criteria:Histologically confirmed diagnosis of squamous cell carcinoma of the anus. Must be able to provide informed consent.
 Exclusion Criteria:History of new malignancy since the time of treatment for anal cancer. Non-English speaking.

Both
30 Years to 70 Years
No
 
United States
 
NCT00568425
 
SU-11062007-812, 96405, ANAL0002, NCT00568425
Stanford University
 
Principal Investigator: Mark Lane Welton Stanford University
Stanford University
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP